# Modulari-T ## Posts - [Hello world!](https://2k5.e3c.myftpupload.com/hello-world/): Welcome to WordPress. This is your first post. Edit or delete it, then start writing! ## Pages - [Our Science](https://2k5.e3c.myftpupload.com/our-science/): Our Science The blueprint was always there.It took 30 years of science to read it. Every company in in vivo cell therapy is using technology that was built for something else. CAR constructs adapted from ex vivo therapy. Delivery vectors borrowed from gene therapy. The field has been innovating around a broken foundation instead of replacing it. Modulari-T built two things from scratch: a next-generation receptor that mirrors the natural architecture of immune cells, and a modular delivery vehicle purpose-designed for in vivo targeting. Together, they form the only complete 2nd generation in vivo CGT system in existence. Only company […] - [Our Pipeline](https://2k5.e3c.myftpupload.com/our-pipeline/): Our Pipeline The science is validated.The pipeline is moving.Patients are waiting. Modulari-T is advancing a diverse pipeline across oncology, autoimmunity, and inflammation— the three therapeutic areas where first-generation cell therapy either failed or never arrived. Our platform enables the development of wholly-owned programs and partnered assets, creating dual pathways to value generation from a single integrated system. Wholly owned lead asset targeting uPAR in oncology will enter IND-enabling studies in 4Q 2026 - [Contact Us](https://2k5.e3c.myftpupload.com/contact-us/): Contact Us The next conversation could change the trajectory.
This is where it starts. Whether you’re exploring a partnership, evaluating the platform, or ready to talk about what comes next in cell therapy, we’d like to hear from you. - [News](https://2k5.e3c.myftpupload.com/news/): NewsThe science is advancing. The pipeline is accelerating. And the milestones are starting to stack. Follow Modulari-T’s progress as we advance the only complete second-generation in vivo cell and gene therapy platform from proof of concept to the clinic. Milestones, publications, partnerships, and the moments that move the science forward. Modulari-T Biosciences Names Tanya E. Borsuk, PhD, as Chief Executive Officer April 21, 2026 Merck Digital Sciences Studio Expands with Second Innovation Class to Advance Biopharma and Digital Health Progress in North America March 13, 2026 - [Homepage](https://2k5.e3c.myftpupload.com/): The Immune SystemHad A Blueprint All Along. We finally built from it. LEARN MORE ABOUT OUR SCIENCE CAR-T was invented before scientists fully understood how T cell receptors work. That single architectural gap created many of the limitations the field still faces today: toxic side effects, lack of persistence, cell exhaustion, relapse, and no path beyond heme malignancies. The Problem Cell therapies changed oncology.They just can’t reach everyone who needs it. Why First-Gen Cell Therapy Falls Short ToxicSide Effects Uncontrolled immune activation limits who can safely receive treatment. Preconditioning Needed The need for the use of toxic chemotherapies and preconditioning […] - [Team](https://2k5.e3c.myftpupload.com/team/): The Modulari-T Team The people who built the first generation. Now building what comes next. Modulari-T’s leadership team and advisory board have direct experience developing, manufacturing, and commercializing the first-generation autologous and in vivo CAR-Ts that created blockbuster brands and defined the fields. Founding Team Built by a tight-knit team with one mission. TanyaBorsuk, PhD CEO DavidCotnoir-White, PhD Co-founder,President & CEO StephanieMok, PhD Co-founder & COO DelphineGuipouy, PhD Co-founder, VP of R&D Why This Team This isn’t a team that licensed existing technology.They built the science it’s based on. Most cell therapy companies start with an existing construct and optimize […] ## Optional - [Agent (MCP protocol)](websites-agents.hostinger.com/2k5.e3c.myftpupload.com/mcp) [comment]: # (Generated by Hostinger Tools Plugin)